686 related articles for article (PubMed ID: 11849789)
41. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
[TBL] [Abstract][Full Text] [Related]
42. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
[TBL] [Abstract][Full Text] [Related]
43. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy.
Hagan M; Zlotecki R; Medina C; Tercilla O; Rivera I; Wajsman Z; Neulander EZ
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):329-40. PubMed ID: 15145145
[TBL] [Abstract][Full Text] [Related]
44. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
Parker CC; Petersen PM; Cook AD; Clarke NW; Catton C; Cross WR; Kynaston H; Parulekar WR; Persad RA; Saad F; Bower L; Durkan GC; Logue J; Maniatis C; Noor D; Payne H; Anderson J; Bahl AK; Bashir F; Bottomley DM; Brasso K; Capaldi L; Chung C; Cooke PW; Donohue JF; Eddy B; Heath CM; Henderson A; Henry A; Jaganathan R; Jakobsen H; James ND; Joseph J; Lees K; Lester J; Lindberg H; Makar A; Morris SL; Oommen N; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Ramani V; Røder A; Sayers I; Simms M; Srinivasan V; Sundaram S; Tarver KL; Tran A; Wells P; Wilson J; Zarkar AM; Parmar MKB; Sydes MR;
Ann Oncol; 2024 Jul; 35(7):656-666. PubMed ID: 38583574
[TBL] [Abstract][Full Text] [Related]
45. [The meaning of PSA progression after radical prostatectomy. Preliminary results].
Luján Galán M; Pascual Mateo C; Rodríguez García N; Chiva Robles V; Escalera Almendros C; Angulo Cuesta J; Berenguer Sánchez A
Actas Urol Esp; 2006 Apr; 30(4):353-8. PubMed ID: 16838606
[TBL] [Abstract][Full Text] [Related]
46. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
[TBL] [Abstract][Full Text] [Related]
49. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
[TBL] [Abstract][Full Text] [Related]
50. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
King CR; Presti JC; Gill H; Brooks J; Hancock SL
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
[TBL] [Abstract][Full Text] [Related]
51. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
52. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience.
Liauw SL; Webster WS; Pistenmaa DA; Roehrborn CG
Urology; 2003 Jun; 61(6):1204-10. PubMed ID: 12809898
[TBL] [Abstract][Full Text] [Related]
53. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose.
Valicenti RK; Gomella LG; Ismail M; Mulholland SG; Strup S; Petersen RO; Corn BW; Lu JD
Urology; 1998 Dec; 52(6):1034-40. PubMed ID: 9836551
[TBL] [Abstract][Full Text] [Related]
54. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
55. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
56. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer.
Buskirk SJ; Schild SE; Durr ED; Robinow JS; Bock FF; Wolfe JT; Tomera KM; Ferrigni RG
Mayo Clin Proc; 1996 Mar; 71(3):242-8. PubMed ID: 8594281
[TBL] [Abstract][Full Text] [Related]
58. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation.
Crane CH; Rich TA; Read PW; Sanfilippo NJ; Gillenwater JY; Kelly MD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):681-6. PubMed ID: 9336150
[TBL] [Abstract][Full Text] [Related]
59. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
60. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy.
D'Amico AV; Whittington R; Malkowicz SB; Loughlin K; Schultz D; Schnall M; Tempany CM; Tomaszewski JE; Renshaw A; Wein A
Urology; 1996 Apr; 47(4):538-47. PubMed ID: 8638365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
